|
more...
“We believe that the uPA system is a promising target for inhibiting tumor growth,
metastasis, and angiogenesis,” said Josh Distler, Attenuon’s chief operating officer. “We
are very excited about this antibody based on the strong preclinical data we have obtained.
Humanizing this antibody using XOMA’s HETM technology is an important milestone in
our effort to develop this potential new treatment option for cancer patients.”
“We are pleased to work with Attenuon to improve the medical and commercial potential
of their antibody candidate through our HETM technology.” said Jack Castello, XOMA’s
chairman of the board, president, and chief executive officer. “We view this agreement
as another step forward in establishing our HETM technology as the basis of a new and
potentially significant line of business for XOMA.”
Human EngineeringTM Technology
HETM technology is a clinically tested humanization technology intended for modifying
non-human antibodies to make them suitable for medical use in humans. XOMA’s
patented HETM technology is distinct from other humanization techniques and is
independent of CDR grafting. HETM technology is based on the conserved structure-
function relationships among antibodies and defines which amino acid residues in a non-
human antibody variable region are candidates for substitution. XOMA’s deliverables
under HETM agreements generally include four HETM antibodies provided in three months,
that have preserved binding, structure, and function and are approximately 95% human.
|